Physician profile
Michael Reiss
NPI 1528157815
$2,155.99
in general payments reported to CMS, 2019-2025
23 companies · $301 in 2025
The $301 reported for 2025 was more than what 85% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $109 · 2021: $112 · 2022: $457 · 2023: $559 · 2024: $229 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $604.57 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Corium, LLC | $252.26 | 2022-2025 | Azstarys |
| Sobi, INC | $198.37 | 2019-2022 | |
| Sanofi Pasteur INC. | $135.49 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $124.26 | 2019-2023 | Jornay Pm |
| Abbott Laboratories | $111.27 | 2023 | |
| Pfizer INC. | $93.91 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $88.15 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Collegium Pharmaceutical, INC. | $86.15 | 2025 | Jornay Pm |
| Neurelis, INC. | $74.15 | 2022-2024 | Valtoco |
| Supernus Pharmaceuticals, INC. | $59.81 | 2021-2023 | Qelbree |
| Seqirus USA INC | $51.72 | 2022-2024 | Flucelvax, Flucelvax Quadrivalent |
| Tris Pharma INC | $49.07 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $44.07 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.08 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $28.21 | 2024 | Briviact |
| Ars Pharmaceuticals Operations, INC. | $22.09 | 2025 | Neffy |
| Neos Therapeutics, LP | $19.67 | 2019 | |
| Abbvie INC. | $18.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.52 | 2024 | |
| Alexion Pharmaceuticals, INC. | $15.24 | 2023 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $14.23 | 2023 | Flumist Quadrivalent |
| Adlon Therapeutics L.P. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Reiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.